drugset / Trial / NCT03087162

Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori

NCT03087162

Phase 4 Completed 180 enrolled Ramathibodi Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

New drug regimen for Helicobacter pylori eradication, the investigators compare once daily dose dexlansoprazole levofloxacin based quadruple therapy and twice daily dose dexlansoprazole levofloxacin quadruple therapy for helicobacter pylori eradication.

Timeline

Start
2017-01-01
Primary completion
2017-12-01
Completion
2017-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexlansoprazole Other / unclassified 60 mg Oral

Indications

No indication recorded.